SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

Add ENTB Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/24/2017 9:00:06 PM - Followers: 445 - Board type: Free - Posts Today: 0

                                     ENTB LATEST NEWS FROM JUNE 1, 2016:






Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328
[email protected]

Web site:


CIK 0001449447

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)

Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.



David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance

 Recent News!

June 1, 2015




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ENTB News: Quarterly Report (10-q) 01/11/2017 10:29:57 AM
ENTB News: Annual Report (10-k) 11/23/2016 06:08:21 AM
#38055   Parris, is that really you? Welcome back. Can't JokersWild12 03/24/17 09:00:06 PM
#38054   ENTB BEEN A LOSER FOR TEN YEARS NOW parrishilton 03/24/17 04:55:07 PM
#38053   From the PR today at RGBP they are JokersWild12 03/23/17 05:47:33 PM
#38052   Fabulous News.Would have made sense to mention ENTB_ZANDER ronrooster 03/23/17 10:39:15 AM
#38051   Related NEWS: RGBP JokersWild12 03/23/17 10:24:21 AM
#38050   I guess ENTB_ZANDER is on the biweekly Thursday ronrooster 03/22/17 10:59:38 AM
#38049   Yes. Hopefully others start seeing the pieces. Obviously JokersWild12 03/20/17 07:11:46 PM
#38048   PR should be out tomorrow or Wednesday. ronrooster 03/20/17 06:18:12 PM
#38047   Wow. Great credentials. This keeps getting better and JokersWild12 03/20/17 06:13:35 PM
#38046   Check out Linda Black's company. ronrooster 03/20/17 05:47:51 PM
#38045   GREAT NEWS!!! ENTB_ZANDER ronrooster 03/20/17 05:40:09 PM
#38044   I like the connections that Debbie Dorsee the JokersWild12 03/18/17 06:13:34 PM
#38043   ENTEST BIOMEDICAL INCORPORATED (OTCMKTS:ENTB) had a decrease of ronrooster 03/17/17 09:50:45 AM
#38042   Getting a lot of volume...gonna get jiggy here soon gotinearly 03/15/17 11:13:18 AM
#38041   ENTB hit 2 million market cap today.News could ronrooster 03/14/17 05:15:44 PM
#38040   WOW!!! 45k shares bot in the last 30 gotinearly 03/14/17 04:06:26 PM
#38039   Big BID, big hits. Kbro13 03/14/17 03:17:12 PM
#38038   Tom Donnelly is also an Professor. High caliber ronrooster 03/11/17 02:09:17 PM
#38037   Great addition. International reputation. He will guide the JokersWild12 03/09/17 11:32:04 AM
#38036   ENTB/ZANDER orchestrated to catapult in the near future.Will ronrooster 03/09/17 10:51:57 AM
#38035   I think I like where this is headed. salesleader 03/09/17 10:37:35 AM
#38034   NEWS. 8:00 AM ET 3/9/17 / PR Newswire. JokersWild12 03/09/17 08:54:12 AM
#38033   Thanks.I am holding tight and dramatically moving up ronrooster 03/07/17 03:35:27 PM
#38032   The veterinary experience Donnelly has will be a JokersWild12 03/07/17 03:30:05 PM
#38031   Fantastic news JW. Any thoughts as to the ronrooster 03/07/17 01:20:03 PM
#38030   New addition to the management team. Note that JokersWild12 03/07/17 12:14:32 PM
#38029   Checkpoint has the license and will pay RGBP gotinearly 03/06/17 08:48:16 AM
#38028   You could be right,however it is not correct ronrooster 03/05/17 02:36:22 PM
#38027   Umm, checkpoint is 100% owned by you gotinearly 03/05/17 02:31:54 PM
#38026   ENTB and RGBP potential comparison re NR2F6. ronrooster 03/05/17 11:32:46 AM
#38025   Funny the market did not recognized the incredible ronrooster 03/02/17 06:44:53 PM
#38024   Sweet news. They are VERY optimistic about NR2F6 JokersWild12 03/02/17 11:09:14 AM
#38023   SAN DIEGO, March 2, 2017 /PRNewswire/ -- ronrooster 03/02/17 10:05:56 AM
#38022   Rgbp news out re NR2F6. With checkpoint.Since Entb ronrooster 03/02/17 10:03:34 AM
#38021   Thanks.gltu ronrooster 03/01/17 03:33:00 PM
#38020   gave you another follower Ron ( for good salesleader 03/01/17 03:10:05 PM
#38019   Agree,17 million float will make Entb EXPLODE. GLTU. ronrooster 03/01/17 02:03:59 PM
#38018   Due to the float size this should roar salesleader 03/01/17 01:43:21 PM
#38017   I agree.Entb current market cap of 1.2 m ronrooster 03/01/17 10:57:52 AM
#38016   It's impossible to prognosticate what this stock(management) will JokersWild12 03/01/17 10:43:10 AM
#38015   This volume level is meaningless. No matter what MrBrakk 03/01/17 10:26:51 AM
#38014   I guess my hunch was out to ronrooster 03/01/17 09:59:51 AM
#38013   I hope your hunch is correct about this JokersWild12 02/27/17 12:44:40 PM
#38012   Just an hunch,imo I forecast an Zander PR ronrooster 02/27/17 10:54:17 AM
#38011   Not sure where this will be then. Many JokersWild12 02/16/17 11:54:18 AM
#38010   Thanks for your thoughts.based on Zander progress lately, ronrooster 02/16/17 11:22:05 AM
#38009   The patent application is evidence that there is JokersWild12 02/16/17 11:06:50 AM
#38008   Am I correct to sumize that this release ronrooster 02/15/17 07:21:41 PM
#38007   News Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, JokersWild12 02/15/17 09:26:40 AM
#38006   You have my luck! bme 02/14/17 11:56:57 PM